GRI Bio, Inc. (GRI)

GRI Bio, Inc.'s share price experienced a substantial decline. The company engaged in equity financing, leading to dilution for existing shareholders. GRI Bio implemented two reverse stock splits to maintain compliance with Nasdaq's minimum bid price requirement.

GRI Bio, Inc.'s products and services do not typically experience demand seasonality. The demand for its product candidates is driven by the progression of clinical trials, regulatory approvals, and the unmet medical needs of patient populations. The company's revenue is currently forecast to be zero next year, as it is still in the development stage.

GRI Bio, Inc. is a clinical-stage biopharmaceutical company focused on discovering, developing, and commercializing therapies for inflammatory, fibrotic, and autoimmune diseases. The company operates in the Health Care sector, specifically in Biotechnology and Drug Discovery, modulating Natural Killer T (NKT) cells to interrupt disease progression and restore immune system homeostasis. Its major product candidates include GRI-0621, an oral inhibitor of type 1 invariant Natural Killer T (iNKT) cells in Phase 2a clinical trials for idiopathic pulmonary fibrosis (IPF); GRI-0803, a novel oral agonist of type 2 Natural Killer T (dNKT) cells in preclinical development for autoimmune disorders; and a proprietary compound library of over 500 compounds.

GRI Bio, Inc. is headquartered in La Jolla, California, United States. The company develops and commercializes therapies for the United States and internationally.

GRI Bio, Inc. announced positive topline data from its Phase 2a study of GRI-0621 in idiopathic pulmonary fibrosis (IPF), demonstrating that the treatment was well tolerated and met its primary endpoint. GRI Bio secured a new U.S. composition of matter patent covering novel compound structures. The company reiterated its Full Year 2025 financial results, strengthened its balance sheet, and summarized key recent highlights. Two analysts have a "Strong Buy" consensus rating for GRI Bio, Inc.. The CEO, Marc Hertz, has been featured in virtual investor segments and the company has participated in virtual conferences.

GRI Bio, Inc.'s ownership structure includes institutional, insider, and public/individual investors. Major institutional owners include Geode Capital Management, Llc, Vanguard Group Inc and BlackRock, Inc.. Key individual and insider owners include Joseph E. Payne, Walter Marc Hertz and Ofir Levi.